Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWenjin Yin
About this trial
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Eligibility criteria
Qualifiers
Aged ≥18 and older
Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
HR+/HER2-
ECOG 0-3
Disqualifiers
During pregnancy or lactation
Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption
Trial design
Treatments tested in this trial
- CDK4/6 inhibitor
Treatment groups
229 Participants
are divided into 1 treatment groupSponsors and collaborators
Wenjin Yin
Lead sponsor
RenJi Hospital
Sponsor institution
Source ClinicalTrials.gov